Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Concordance between changes in serum thymidine kinase and changes in Ki-67 by palbociclib

From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

  Ki-67 ↓ (N) Ki-67 ↑ (N) Total (N)
TK ↓ (n) 32 4a 36
TK ↑ (n) 2a 21 23
Total (n) 34 25 59
  1. TK, Thymidine kinase
  2. a Discordant cases
Back to article page